SMITHKLINE AUGMENTIN SALES JUMP 73% IN U.S. DURING STRONG FIRST QUARTER FLU SEASON; BRISTOL PRAVACHOL SALES UP 48% TO $374 MIL., TAXOL GROWS BY 10%
SmithKline Beecham's antibiotic Augmentin soared to a 73% sales increase in the U.S. during the first quarter as a strong flu season helped produce dramatic increases in sales for anti-infective products across the industry. Augmentin posted $204 mil. in sales for the quarter in the U.S. and was SB's number one product for the period. Worldwide sales reached $419 mil., a 29% increase. SB calculates its sales figures at actual average rates of exchange and uses comparable exchange rates to calculate increases.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth